Clearside Biomedical (CLSD) Competitors $0.87 +0.02 (+2.55%) Closing price 04:00 PM EasternExtended Trading$0.85 -0.02 (-1.80%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. RNAC, TSVT, INZY, GLUE, PVLA, LFCR, TNGX, GOSS, CRVS, and AQSTShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Cartesian Therapeutics 2seventy bio Inozyme Pharma Monte Rosa Therapeutics Palvella Therapeutics Lifecore Biomedical Tango Therapeutics Gossamer Bio Corvus Pharmaceuticals Aquestive Therapeutics Clearside Biomedical (NASDAQ:CLSD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do institutionals and insiders hold more shares of CLSD or RNAC? 18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 9.2% of Clearside Biomedical shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, CLSD or RNAC? Clearside Biomedical has higher earnings, but lower revenue than Cartesian Therapeutics. Clearside Biomedical is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$1.66M40.20-$32.49M-$0.41-2.11Cartesian Therapeutics$34.17M6.95-$219.71M-$52.83-0.17 Does the media prefer CLSD or RNAC? In the previous week, Cartesian Therapeutics had 8 more articles in the media than Clearside Biomedical. MarketBeat recorded 13 mentions for Cartesian Therapeutics and 5 mentions for Clearside Biomedical. Cartesian Therapeutics' average media sentiment score of 0.42 beat Clearside Biomedical's score of -0.13 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearside Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor CLSD or RNAC? Clearside Biomedical received 337 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 67.26% of users gave Clearside Biomedical an outperform vote. CompanyUnderperformOutperformClearside BiomedicalOutperform Votes37667.26% Underperform Votes18332.74% Cartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88% Is CLSD or RNAC more profitable? Clearside Biomedical has a net margin of -413.83% compared to Cartesian Therapeutics' net margin of -510.72%. Company Net Margins Return on Equity Return on Assets Clearside Biomedical-413.83% N/A -92.90% Cartesian Therapeutics -510.72%N/A -6.03% Do analysts prefer CLSD or RNAC? Clearside Biomedical presently has a consensus price target of $5.00, suggesting a potential upside of 477.63%. Cartesian Therapeutics has a consensus price target of $42.50, suggesting a potential upside of 364.48%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, equities analysts clearly believe Clearside Biomedical is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk & volatility, CLSD or RNAC? Clearside Biomedical has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. SummaryCartesian Therapeutics beats Clearside Biomedical on 9 of the 17 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.89M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.929.0626.7119.71Price / Sales40.20251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book-3.466.456.774.50Net Income-$32.49M$143.98M$3.23B$248.22M7 Day Performance0.13%2.41%1.80%0.56%1 Month Performance8.20%4.56%11.10%13.17%1 Year Performance-35.88%-2.67%17.11%7.30% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical2.2912 of 5 stars$0.87+2.5%$5.00+477.6%-43.3%$66.89M$1.66M-1.9230RNACCartesian Therapeutics1.5471 of 5 stars$10.37+1.1%$42.50+309.8%-62.3%$269.14M$34.17M-0.2064News CoverageAnalyst RevisionTSVT2seventy bio1.5578 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440Positive NewsINZYInozyme Pharma3.0315 of 5 stars$3.99+1.0%$11.75+194.5%-16.0%$257.60MN/A-2.5650High Trading VolumeGLUEMonte Rosa Therapeutics2.1813 of 5 stars$4.11+3.3%$15.50+277.1%-6.6%$252.81M$159.49M-2.2590Positive NewsAnalyst DowngradePVLAPalvella Therapeutics3.8018 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AEarnings ReportAnalyst RevisionLFCRLifecore Biomedical1.2515 of 5 stars$6.71-2.6%$8.00+19.2%+8.2%$248.44M$130.31M-11.98690News CoverageAnalyst ForecastTNGXTango Therapeutics1.8933 of 5 stars$2.29+52.7%$12.33+438.6%-74.7%$248.22M$40.99M-1.9490Positive NewsHigh Trading VolumeGOSSGossamer Bio3.7553 of 5 stars$1.09+4.8%$7.75+611.0%+71.6%$247.67M$114.70M-3.41180Earnings ReportAnalyst RevisionCRVSCorvus Pharmaceuticals2.3916 of 5 stars$3.62+0.3%$16.33+351.2%+66.5%$246.77MN/A-3.8930Analyst ForecastAQSTAquestive Therapeutics1.2964 of 5 stars$2.45+2.9%$10.67+335.4%-28.6%$243.35M$54.23M-5.44160Positive NewsAnalyst RevisionGap Up Related Companies and Tools Related Companies Cartesian Therapeutics Competitors 2seventy bio Competitors Inozyme Pharma Competitors Monte Rosa Therapeutics Competitors Palvella Therapeutics Competitors Lifecore Biomedical Competitors Tango Therapeutics Competitors Gossamer Bio Competitors Corvus Pharmaceuticals Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
